SCHEMBL5151649

SCHEMBL5151649

COc1cc([N+](=O)[O-])ccc1S(=O)(=O)N=CN(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
ALPL P05186 2/20 0.46
TDP1 Q9NUW8 1/20 0.43
PTGS2 P35354 2/20 0.42
LMNA P02545 3/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
ALDH1A1 P00352 7/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
PDE2A O00408 1/20 0.41
PDE5A O76074 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41
APEX1 P27695 1/20 0.41
PDE4A P27815 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151645 1.00 HTT (0.48) HTTALPLTDP1PTGS2LMNA
SCHEMBL14336285 1.00 HTT (0.48) HTTALPLTDP1PTGS2LMNA
SCHEMBL5151379 0.82 POLB (0.46) HTTTDP1PTGS2LMNAGAA
SCHEMBL5151374 0.82 POLB (0.46) HTTTDP1PTGS2LMNAGAA
SCHEMBL14336274 0.82 POLB (0.46) HTTTDP1PTGS2LMNAGAA
SCHEMBL19551627 0.79 ALDH1A1 (0.48) HTTTDP1LMNAGAAALDH1A1
SCHEMBL19551624 0.79 ALDH1A1 (0.48) HTTTDP1LMNAGAAALDH1A1
SCHEMBL19552197 0.79 ALDH1A1 (0.46) HTTTDP1LMNAGAAALDH1A1
SCHEMBL19552196 0.79 ALDH1A1 (0.46) HTTTDP1LMNAGAAALDH1A1
SCHEMBL14336403 0.79 GAA (0.42) HTTLMNAGAAPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312225-B2 Macrocyclic pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AG (DE) 2007-12-25 US disclosed
EP-1530574-B1 MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS SCHERING AG (DE) 2006-11-22 EP disclosed
EP-1530574-A1 MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-05-18 EP disclosed
US-20040209895-A1 inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases SCHERING AG (DE) 2004-10-21 US disclosed
WO-2004026881-A1 MACROCYCLIC PYRIMIDINES, THE PRODUCTION THEREOF AND THE USE OF THE SAME AS MEDICAMENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209895-A1 inhibit cyclin-dependent kinases and VEGF-receptor tyrosine kinases CCNK, CDK2, CDK1 HTT 4545/4885ALPL 4580/4885TDP1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.